Noticias de REVB_US

Noticias del mercado

Últimas noticias sobre REVB_US — 142 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: REVB_US ✕ 142 resultados

08/05/2026 REVB_US — Newser

The edge Revelation Biosciences (REVB) has in a competitive landscape (Risk Aversion) 2026-05-08 - Gap Fill Strategy

08/05/2026 REVB_US — The Legal Advocate

The edge Revelation Biosciences (REVB) has in a competitive landscape (Risk Aversion) 2026-05-08 - Ease of Movement

08/05/2026 REVB_US — Yahoo Finance

REVB Poised for Big Year

07/05/2026 REVB_US — SEC.gov

EX-99.1

07/05/2026 REVB_US — Eagle-Tribune

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

SAN DIEGO, CA / ACCESS Newswire / 7 de mayo de 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (la "Compañía" o "Revelation"), una empresa de ciencias biológicas en etapa clínica que desarrolla soluciones innovadoras para tratar enfermedades agudas

07/05/2026 REVB_US — TradingView

BRIEF-Revelation Biosciences Inc Q1 EPS USD -2.71

07 mayo (Reuters) - Ingresos netos del primer trimestre de Revelation Biosciences Inc: -3 millones de dólares.

07/05/2026 REVB_US — MarketScreener

Revelation Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026

07/05/2026 REVB_US — geneonline.com

Revelation Biosciences Inc. Announces First Quarter 2026 Financial Results Ending March 31

Revelation Biosciences Inc. publicó su resultado financiero […]

07/05/2026 REVB_US — Newswire.com

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

Revelation Biosciences, Inc. (NASDAQ:REVB) (la "Compañía" o "Revelation"), una empresa de ciencias biológicas en etapa clínica que desarrolla soluciones innovadoras...

07/05/2026 REVB_US — Stock Titan

FDA agrees to single Gemini study for acute kidney injury

07/05/2026 REVB_US — Stock Titan

Q1 2026 results for Revelation Biosciences (NASDAQ: REVB) detailed

07/05/2026 REVB_US — Stock Titan

Revelation Biosciences (REVB) Q1 loss widens as cash runway and going concern risks emerge

07/05/2026 REVB_US — Corsicana Daily Sun

Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026

04/05/2026 REVB_US — TradingView

Revelation Biosciences Inc expected to post a loss of $1.15 a share - Earnings Preview

01/05/2026 REVB_US — Stock Titan

Revelation Biosciences (REVB) CFO reports tax-withholding share sale via trust